by Annabel Sedgwick
Share
by Annabel Sedgwick
Share
Mosaic Surgical Ltd, based in High Wycombe, UK, is pleased to announce a new fixed fee service for UKCA marking with a UK notified body that will support manufacturers and distributors of surgical products that previously traded under EU law and CE marking before Brexit, and help to ensure continuity of production, conformity with sales legislation and, crucially, uninterrupted trade in the UK. New legislation for marketing products in the UK came into force on January the 1st 2021, stipulating that most goods previously subject to the CE marking must now comply with and display UKCA marking instead.
The County Mayo-based company Idoman Teoranta was the first to recognise the value of Mosaic Surgical’s newly launched service, and has already entered into an agreement to deliver UKCA marking for its Thermablate EAS™, a handheld automated device for treatment of heavy menstrual bleeding. Manufactured by Idoman and distributed by JUNE Medical, Thermablate EAS offers fast, safe and effective ablation treatment in just three minutes. Under the agreement, Mosaic Surgical will assume the role of the UK Responsible Person, providing a cost-effective route to UKCA marking. Other well-known companies that have also engaged Mosaic Surgical as their UK representative include Synergo Medical and Neomedic.
To learn more about Mosaic Surgical UKCA service, visit https://mosaicsurgical.com/ukca-rep
To read more about Mosaic Surgical, visit www.mosaicsurgical.com
About Mosaic Surgical Ltd
Mosaic Surgical Ltd is the manufacturing arm of a group of trusted medical devices companies.
About JUNE Medical Group
JUNE Medical Group is an award winning medical device distributor with offices in the UK, USA and Sweden. Galaxy II self retaining retractor.
Microban® International – the global leader in antimicrobial additives and odor control solutions – has released a statement discrediting unwarranted claims about the safety and efficacy of antimicrobial technologies. This statement is intended to ensure that the public, consumers, and other stakeholders are equipped to make fully informed decisions, based on scientific reasoning. Making a clear distinction between public health and non-public health claims, Microban has explained the advantages of incorporating its antimicrobial additives into
Anion dysregulation is seen in numerous diseases, from cystic fibrosis and chronic pain, to autism and cancer. Researchers at the University of Dallas are investigating anion transport in vivo, developing novel tools to help analyze the effects of both normal and aberrant anion regulation at the molecular level, and are using INTEGRA’s PIPETBOY acu 2 to streamline their cell
June Medical is one of 48 organisations to be recognised for their excellence in innovation in this year’s Queen’s Awards for Enterprise. Now in its 55th year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country – rewarding only the most outstanding achievements – with winning businesses able to use the esteemed
A report from the International Agency for Research on Cancer1 recently classified TiO2 as ‘possibly carcinogenic to humans’ by inhalation and similarly, the European Chemicals Agency2 recommended TiO2 be classified as a category 2 carcinogen (suspected of causing cancer). In contrast, antimicrobial technologies from Microban International are based on SilverShield®, the first patented antimicrobial solution